362 related articles for article (PubMed ID: 9375961)
1. Purification of 5-hydroxytryptamine3 receptors from porcine brain.
Fletcher S; Barnes NM
Br J Pharmacol; 1997 Oct; 122(4):655-62. PubMed ID: 9375961
[TBL] [Abstract][Full Text] [Related]
2. Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron.
Steward LJ; Ge J; Bentley KR; Barber PC; Hope AG; Lambert JJ; Peters JA; Blackburn TP; Barnes NM
Br J Pharmacol; 1995 Sep; 116(2):1781-8. PubMed ID: 8528560
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical properties of serotonin 5-HT3 binding sites solubilized from membranes of NG 108-15 neuroblastoma-glioma cells.
Miquel MC; Emerit MB; Bolaños FJ; Schechter LE; Gozlan H; Hamon M
J Neurochem; 1990 Nov; 55(5):1526-36. PubMed ID: 2213008
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
[TBL] [Abstract][Full Text] [Related]
5. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain.
Parker RM; Barnes JM; Ge J; Barber PC; Barnes NM
J Neurol Sci; 1996 Dec; 144(1-2):119-27. PubMed ID: 8994113
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of 5-hydroxytryptamine3 receptors in murine brain and ileum using the novel radioligand [3H]RS-42358-197: evidence for receptor heterogeneity.
Bonhaus DW; Wong EH; Stefanich E; Kunysz EA; Eglen RM
J Neurochem; 1993 Nov; 61(5):1927-32. PubMed ID: 8229003
[TBL] [Abstract][Full Text] [Related]
7. [3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes.
Gordon JC; Barefoot DS; Sarbin NS; Pinkus LM
J Pharmacol Exp Ther; 1989 Dec; 251(3):962-8. PubMed ID: 2600824
[TBL] [Abstract][Full Text] [Related]
8. Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]RS-42358-197.
Wong EH; Bonhaus DW; Wu I; Stefanich E; Eglen RM
J Neurochem; 1993 Mar; 60(3):921-30. PubMed ID: 8436978
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
Kidd FJ; Levy JC; Nielsen M; Hamon M; Gozlan H
Eur J Pharmacol; 1993 Sep; 247(1):45-56. PubMed ID: 8258360
[TBL] [Abstract][Full Text] [Related]
10. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
11. [3H]zacopride: ligand for the identification of 5-HT3 recognition sites.
Barnes NM; Costall B; Naylor RJ
J Pharm Pharmacol; 1988 Aug; 40(8):548-51. PubMed ID: 2907008
[TBL] [Abstract][Full Text] [Related]
12. Distribution of S(-)-zacopride-insensitive [125I]R(+)-zacopride binding sites in the rat brain and peripheral tissues.
Ge J; Barnes JM; Towers P; Barnes NM
Eur J Pharmacol; 1997 Aug; 332(3):307-12. PubMed ID: 9300265
[TBL] [Abstract][Full Text] [Related]
13. Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors.
Hewlett WA; Trivedi BL; Zhang ZJ; de Paulis T; Schmidt DE; Lovinger DM; Ansari MS; Ebert MH
J Pharmacol Exp Ther; 1999 Jan; 288(1):221-31. PubMed ID: 9862774
[TBL] [Abstract][Full Text] [Related]
14. Characterization of desamino-5-[125I]iodo-3-methoxy-zacopride ([125I]MIZAC) binding to 5-HT3 receptors in the rat brain.
Hewlett WA; Fridman S; Trivedi BL; Schmidt DE; de Paulis T; Ebert MH
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Feb; 22(2):397-410. PubMed ID: 9608609
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and radiolabeling of (S)-4-amino-5-iodo-2-methoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide, the active enantiomer of [125I]iodozacopride, and re-evaluation of its 5-HT3 receptor affinity.
Hewlett WA; de Paulis T; Mason NS; Schmidt DE; Trivedi BL; Zhang ZJ; Ebert MH
Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2079-84. PubMed ID: 9433779
[TBL] [Abstract][Full Text] [Related]
16. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.
Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H
Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509
[TBL] [Abstract][Full Text] [Related]
17. Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain.
Fletcher S; Barnes NM
Brain Res; 1996 Aug; 729(2):281-4. PubMed ID: 8877001
[TBL] [Abstract][Full Text] [Related]
18. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Barnes JM; Barnes NM
Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
[TBL] [Abstract][Full Text] [Related]
19. Solubilization of a 5-HT3 binding site from rabbit small bowel muscularis membranes.
Gordon JC; Sarbin NS; Barefoot DS; Pinkus LM
Eur J Pharmacol; 1990 Jun; 188(6):313-9. PubMed ID: 2373145
[TBL] [Abstract][Full Text] [Related]
20. Purification of the 5-hydroxytryptamine 5-HT3 receptor from NCB20 cells.
McKernan RM; Gillard NP; Quirk K; Kneen CO; Stevenson GI; Swain CJ; Ragan CI
J Biol Chem; 1990 Aug; 265(23):13572-7. PubMed ID: 2380174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
